{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:06Z","timestamp":1790958546111,"version":"4.1.0"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.biopha.2025.118058","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T15:54:41Z","timestamp":1745078081000},"page":"118058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)"],"prefix":"10.1016","volume":"187","author":[{"given":"Ajit Kumar","family":"Navin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalikkaran Thilakan","family":"Rejani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2909-5755","authenticated-orcid":false,"given":"Ashish","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/1940-6207.CAPR-08-0225","article-title":"Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro","volume":"3","author":"Adams","year":"2010","journal-title":"Cancer Prev. Res (Philos. )"},{"key":"10.1016\/j.biopha.2025.118058_bib3","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib4","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118058_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"11","key":"10.1016\/j.biopha.2025.118058_bib7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J. Clin. Pr."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1021\/jf049144d","article-title":"Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability","volume":"53","author":"Cerda","year":"2005","journal-title":"J. Agric. Food Chem."},{"issue":"25","key":"10.1016\/j.biopha.2025.118058_bib9","doi-asserted-by":"crossref","first-page":"10476","DOI":"10.1021\/jf0723864","article-title":"Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans","volume":"55","author":"Espin","year":"2007","journal-title":"J. Agric. Food Chem."},{"issue":"20","key":"10.1016\/j.biopha.2025.118058_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/nu15204441","article-title":"Pharmacological Effects of Urolithin A and Its Role in Muscle Health and Performance: Current Knowledge and Prospects","volume":"15","author":"Zhao","year":"2023","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib11","article-title":"Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults","volume":"3","author":"Singh","year":"2022","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.biopha.2025.118058_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102406","article-title":"Targeting aging with urolithin A in humans: A systematic review","volume":"100","author":"Kuerec","year":"2024","journal-title":"Ageing Res Rev."},{"issue":"9","key":"10.1016\/j.biopha.2025.118058_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2174\/1568009622666220602125343","article-title":"The therapeutic potential of urolithin A for cancer treatment and prevention","volume":"22","author":"Rogovskii","year":"2022","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbagen.2017.10.006","article-title":"An increased autophagic flux contributes to the anti-inflammatory potential of urolithin A in macrophages","volume":"1862","author":"Boakye","year":"2018","journal-title":"Biochim Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.biopha.2025.118058_bib15","doi-asserted-by":"crossref","first-page":"5194508","DOI":"10.1155\/2020\/5194508","article-title":"Ellagic acid-derived urolithins as modulators of oxidative stress","volume":"2020","author":"Djedjibegovic","year":"2020","journal-title":"Oxid. Med Cell Longev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12192-020-01189-8","article-title":"Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells","volume":"26","author":"El-Wetidy","year":"2021","journal-title":"Cell Stress Chaperon-.-."},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nm.4132","article-title":"Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents","volume":"22","author":"Ryu","year":"2016","journal-title":"Nat. Med"},{"issue":"Pt A","key":"10.1016\/j.biopha.2025.118058_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.fct.2017.07.050","article-title":"Safety assessment of Urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant derived ellagitannins and ellagic acid","volume":"108","author":"Heilman","year":"2017","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.biopha.2025.118058_bib19","article-title":"Urolithins: the colon microbiota metabolites as endocrine modulators: prospects and perspectives","volume":"8","author":"Vini","year":"2021","journal-title":"Front Nutr."},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.biopha.2025.118058_bib23","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib24","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.18632\/oncotarget.12554","article-title":"Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles","volume":"8","author":"Hoang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib25","first-page":"1","article-title":"Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer","volume":"10","author":"Boudadi","year":"2016","journal-title":"Clin. Med Insights Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118058_bib26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.7150\/jca.32497","article-title":"Emerging role of glucocorticoid receptor in castration resistant prostate cancer: a potential therapeutic target","volume":"11","author":"Kumar","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2025.118058_bib28","doi-asserted-by":"crossref","first-page":"1437179","DOI":"10.3389\/fendo.2024.1437179","article-title":"Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalk","volume":"15","author":"Hiltunen","year":"2024","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"12","key":"10.1016\/j.biopha.2025.118058_bib29","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1210\/endo.138.12.5564","article-title":"Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression but differ in their growth-stimulating properties of LNCaP cells","volume":"138","author":"Cleutjens","year":"1997","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib30","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-12-2350","article-title":"FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells","volume":"73","author":"Sahu","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12672-014-0173-2","article-title":"Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer","volume":"5","author":"Isikbay","year":"2014","journal-title":"Horm. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ccr.2009.11.006","article-title":"Steroid hormone receptors in prostate cancer: a hard habit to break?","volume":"16","author":"Attard","year":"2009","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaci.2013.09.007","article-title":"The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease","volume":"132","author":"Oakley","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9060067","article-title":"Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance","volume":"9","author":"Crona","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib36","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/bjc.1998.635","article-title":"Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours","volume":"78","author":"Baudin","year":"1998","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41374-021-00716-0","article-title":"Advances in neuroendocrine prostate cancer research: from model construction to molecular network analyses","volume":"102","author":"Shui","year":"2022","journal-title":"Lab Invest"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032046","article-title":"AR and PI3K\/AKT in prostate cancer: a tale of two interconnected pathways","volume":"24","author":"Tortorella","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/1535-7163.MCT-18-0464","article-title":"Urolithin A, a novel natural compound to target PI3K\/AKT\/mTOR pathway in pancreatic cancer","volume":"18","author":"Totiger","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.biopha.2025.118058_bib41","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41416-020-0834-6","article-title":"Emerging role of PTEN loss in evasion of the immune response to tumours","volume":"122","author":"Vidotto","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib42","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib43","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib44","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med"},{"issue":"11","key":"10.1016\/j.biopha.2025.118058_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"39","key":"10.1016\/j.biopha.2025.118058_bib46","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.biopha.2025.118058_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118058_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fendo.2017.00002","article-title":"Non-genomic actions of the androgen receptor in prostate cancer","volume":"8","author":"Leung","year":"2017","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"12","key":"10.1016\/j.biopha.2025.118058_bib49","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/ptr.4941","article-title":"Extracts from Epilobium sp. herbs, their components and gut microbiota metabolites of Epilobium ellagitannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion","volume":"27","author":"Stolarczyk","year":"2013","journal-title":"Phytother. Res"},{"issue":"19","key":"10.1016\/j.biopha.2025.118058_bib50","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/jnci\/91.19.1663","article-title":"Growth regulation of prostatic stromal cells by prostate-specific antigen","volume":"91","author":"Sutkowski","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012107","article-title":"Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer","volume":"5","author":"Gannon","year":"2010","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.105","article-title":"ROS homeostasis and metabolism: a dangerous liason in cancer cells","volume":"7","author":"Panieri","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118058_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2022.112067","article-title":"Balanced basal-levels of ROS (redox-biology), and very-low-levels of pro-inflammatory cytokines (cold-inflammaging), as signaling molecules can prevent or slow-down overt-inflammaging, and the aging-associated decline of adaptive-homeostasis","volume":"172","author":"Wei","year":"2023","journal-title":"Exp. Gerontol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib54","first-page":"6066","article-title":"Induction of oxidative stress by anticancer drugs in the presence and absence of cells","volume":"14","author":"Yokoyama","year":"2017","journal-title":"Oncol. Lett."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118058_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jsbmb.2010.10.009","article-title":"Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1alpha in a low androgen environment","volume":"123","author":"Mitani","year":"2011","journal-title":"J. Steroid Biochem Mol. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/biom9040131","article-title":"Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling","volume":"9","author":"Takayama","year":"2019","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.biopha.2025.118058_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100352","article-title":"Targeting Crosstalk between Nrf-2, NF-kappaB and Androgen Receptor Signaling in Prostate Cancer","volume":"10","author":"Khurana","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib58","article-title":"Oxidative stress and antioxidant status in high-risk prostate cancer subjects","volume":"10","author":"Shukla","year":"2020","journal-title":"Diagn. (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-kappaB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Res"},{"issue":"7354","key":"10.1016\/j.biopha.2025.118058_bib60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2025.118058_bib61","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"20","key":"10.1016\/j.biopha.2025.118058_bib62","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1101\/gad.225680.113","article-title":"The emerging role of the Nrf2-Keap1 signaling pathway in cancer","volume":"27","author":"Jaramillo","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2025.118058_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113946","article-title":"Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer","volume":"177","author":"Yu","year":"2020","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib64","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s41467-017-01269-x","article-title":"Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer","volume":"8","author":"Samaranayake","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087204","article-title":"Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells","volume":"9","author":"Schultz","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib66","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jcb.21707","article-title":"Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities","volume":"104","author":"Plati","year":"2008","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.biopha.2025.118058_bib67","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35","author":"Mohammad","year":"2015","journal-title":"Semin Cancer Biol."},{"issue":"3-4","key":"10.1016\/j.biopha.2025.118058_bib68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/A:1015583310759","article-title":"Regulation of apoptosis in prostate cancer","volume":"20","author":"Gurumurthy","year":"2001","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib69","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2741\/4443","article-title":"The PI3K\/AKT pathway in the pathogenesis of prostate cancer","volume":"21","author":"Chen","year":"2016","journal-title":"Front Biosci. (Landmark Ed. )"},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib70","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/pros.21293","article-title":"Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I\/PI3K\/Akt signaling in human prostate cancer epithelial cells","volume":"71","author":"Liu","year":"2011","journal-title":"Prostate"},{"issue":"15","key":"10.1016\/j.biopha.2025.118058_bib71","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"55","key":"10.1016\/j.biopha.2025.118058_bib72","doi-asserted-by":"crossref","first-page":"7647","DOI":"10.1038\/sj.onc.1210572","article-title":"Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity","volume":"26","author":"Kikuno","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib73","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2025.118058_bib74","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","article-title":"Cancer-related inflammation and treatment effectiveness","volume":"15","author":"Diakos","year":"2014","journal-title":"Lancet Oncol."},{"issue":"6 Pt 1","key":"10.1016\/j.biopha.2025.118058_bib75","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1097\/01.ju.0000085381.20139.b6","article-title":"Molecular pathways to prostate cancer","volume":"170","author":"Gonzalgo","year":"2003","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc2067","article-title":"The tumour microenvironment as a target for chemoprevention","volume":"7","author":"Albini","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"7203","key":"10.1016\/j.biopha.2025.118058_bib77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"6917","key":"10.1016\/j.biopha.2025.118058_bib78","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib79","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/bju.12452","article-title":"Inflammation and prostate cancer: the role of interleukin 6 (IL-6)","volume":"113","author":"Nguyen","year":"2014","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib80","first-page":"141","article-title":"Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro","volume":"57","author":"Okamoto","year":"1997","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.biopha.2025.118058_bib81","first-page":"4640","article-title":"Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor","volume":"58","author":"Hobisch","year":"1998","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/j.biopha.2025.118058_bib82","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-09-0640","article-title":"Interleukin-6 regulates androgen synthesis in prostate cancer cells","volume":"15","author":"Chun","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"44","key":"10.1016\/j.biopha.2025.118058_bib83","doi-asserted-by":"crossref","first-page":"37570","DOI":"10.1074\/jbc.M112.398925","article-title":"Activation of nuclear factor kappaB (NF-kappaB) in prostate cancer is mediated by protein kinase C epsilon (PKCepsilon)","volume":"287","author":"Garg","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.biopha.2025.118058_bib84","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1158\/0008-5472.CAN-12-4537","article-title":"ETS transcription factor ESE1\/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kappaB and drives prostate cancer progression","volume":"73","author":"Longoni","year":"2013","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib85","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neo.2017.02.002","article-title":"Targeting NF-kappa B signaling by artesunate restores sensitivity of castrate-resistant prostate cancer cells to antiandrogens","volume":"19","author":"Nunes","year":"2017","journal-title":"Neoplasia"},{"issue":"28","key":"10.1016\/j.biopha.2025.118058_bib86","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/onc.2014.302","article-title":"Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression","volume":"34","author":"Jin","year":"2015","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.biopha.2025.118058_bib87","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1158\/0008-5472.CAN-08-0107","article-title":"The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth","volume":"68","author":"Jin","year":"2008","journal-title":"Cancer Res"},{"issue":"288","key":"10.1016\/j.biopha.2025.118058_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/stke.2882005pe27","article-title":"Crossroads of estrogen receptor and NF-kappaB signaling","volume":"2005","author":"Biswas","year":"2005","journal-title":"Sci. STKE"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/mend.12.1.0044","article-title":"Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism","volume":"12","author":"McKay","year":"1998","journal-title":"Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib90","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ijc.22802","article-title":"Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo","volume":"121","author":"Nelius","year":"2007","journal-title":"Int J. Cancer"},{"issue":"39","key":"10.1016\/j.biopha.2025.118058_bib91","doi-asserted-by":"crossref","first-page":"24151","DOI":"10.1074\/jbc.271.39.24151","article-title":"Mutual transcriptional interference between RelA and androgen receptor","volume":"271","author":"Palvimo","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib92","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.cellsig.2006.12.012","article-title":"NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells","volume":"19","author":"Lessard","year":"2007","journal-title":"Cell Signal"},{"issue":"18","key":"10.1016\/j.biopha.2025.118058_bib93","doi-asserted-by":"crossref","first-page":"8173","DOI":"10.18632\/oncotarget.2303","article-title":"A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFkappaB and androgen receptor signaling in prostate cancer","volume":"5","author":"Campa","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118058_bib94","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejphar.2018.06.023","article-title":"Urolithin A attenuates pro-inflammatory mediator production by suppressing PI3-K\/Akt\/NF-kappaB and JNK\/AP-1 signaling pathways in lipopolysaccharide-stimulated RAW264 macrophages: Possible involvement of NADPH oxidase-derived reactive oxygen species","volume":"833","author":"Komatsu","year":"2018","journal-title":"Eur. J. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071792","article-title":"Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review","volume":"14","author":"Cattrini","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1758834014529176","article-title":"Castration-resistant prostate cancer: latest evidence and therapeutic implications","volume":"6","author":"Suzman","year":"2014","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.biopha.2025.118058_bib97","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib98","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40520-017-0826-4","article-title":"223)Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature","volume":"30","author":"De Vincentis","year":"2018","journal-title":"Aging Clin. Exp. Res"},{"key":"10.1016\/j.biopha.2025.118058_bib99","first-page":"339","article-title":"Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate Cancer, Version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib101","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s10637-018-0653-2","article-title":"Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer","volume":"36","author":"Sobhani","year":"2018","journal-title":"Invest N. Drugs"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib102","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/01635580801947674","article-title":"Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo","volume":"60","author":"Lee","year":"2008","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.biopha.2025.118058_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116034","article-title":"Targeted therapies of curcumin focus on its therapeutic benefits in cancers and human health: Molecular signaling pathway-based approaches and future perspectives","volume":"170","author":"Islam","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118058_bib104","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.biopha.2018.11.075","article-title":"Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases","volume":"109","author":"Pannu","year":"2019","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2025.118058_bib105","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3389\/fphar.2018.01534","article-title":"A review of resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy","volume":"9","author":"Xiao","year":"2018","journal-title":"Front Pharm."},{"issue":"20","key":"10.1016\/j.biopha.2025.118058_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/nu15204486","article-title":"The pharmacological properties of red grape polyphenol resveratrol: clinical trials and obstacles in drug development","volume":"15","author":"Farhan","year":"2023","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib107","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/1534735416656052","article-title":"Fish-derived omega-3 fatty acids and prostate cancer: a systematic review","volume":"16","author":"Aucoin","year":"2017","journal-title":"Integr. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118058_bib108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12916-014-0234-y","article-title":"Nutrition, dietary interventions and prostate cancer: the latest evidence","volume":"13","author":"Lin","year":"2015","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib109","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s43856-024-00456-4","article-title":"A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation","volume":"4","author":"Robitaille","year":"2024","journal-title":"Commun. Med (Lond. )"},{"key":"10.1016\/j.biopha.2025.118058_bib110","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/270418","article-title":"Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far","volume":"2013","author":"Espin","year":"2013","journal-title":"Evid. Based Complement Altern. Med"},{"issue":"37","key":"10.1016\/j.biopha.2025.118058_bib111","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1021\/jf402498b","article-title":"Time course production of urolithins from ellagic acid by human gut microbiota","volume":"61","author":"Garcia-Villalba","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.biopha.2025.118058_bib112","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2015.03.024","article-title":"Preparative isolation and purification of urolithins from the intestinal metabolites of pomegranate ellagitannins by high-speed counter-current chromatography","volume":"990","author":"Zhao","year":"2015","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib113","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00394-015-1131-7","article-title":"Antiproliferative activity of the ellagic acid-derived gut microbiota isourolithin A and comparison with its urolithin A isomer: the role of cell metabolism","volume":"56","author":"Gonzalez-Sarrias","year":"2017","journal-title":"Eur. J. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201500901","article-title":"Urolithins, the rescue of \"old\" metabolites to understand a \"new\" concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status","volume":"61","author":"Tomas-Barberan","year":"2017","journal-title":"Mol. Nutr. Food Res"},{"key":"10.1016\/j.biopha.2025.118058_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.647582","article-title":"Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review","volume":"8","author":"Al-Harbi","year":"2021","journal-title":"Front Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib116","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00394-015-1061-4","article-title":"Gastrointestinal stability of urolithins: an in vitro approach","volume":"56","author":"Mena","year":"2017","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.biopha.2025.118058_bib117","doi-asserted-by":"crossref","first-page":"6480848","DOI":"10.1155\/2023\/6480848","article-title":"The gut microbiota metabolite urolithin B prevents colorectal carcinogenesis by remodeling microbiota and PD-L1\/HLA-B","volume":"2023","author":"Wang","year":"2023","journal-title":"Oxid. Med Cell Longev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib118","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mc.22746","article-title":"Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells","volume":"57","author":"Zhao","year":"2018","journal-title":"Mol. Carcinog."},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib119","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10637-017-0483-7","article-title":"Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells","volume":"35","author":"Liberal","year":"2017","journal-title":"Invest N. Drugs"},{"issue":"10","key":"10.1016\/j.biopha.2025.118058_bib120","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/mc.22848","article-title":"A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer","volume":"57","author":"Dahiya","year":"2018","journal-title":"Mol. Carcinog."},{"issue":"18","key":"10.1016\/j.biopha.2025.118058_bib121","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1021\/jf4007505","article-title":"The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2\/BCRP)","volume":"61","author":"Gonzalez-Sarrias","year":"2013","journal-title":"J. Agric. Food Chem."},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib122","article-title":"Redox system and oxidative stress-targeted therapeutic approaches in bladder cancer","volume":"13","author":"Dugbartey","year":"2024","journal-title":"Antioxid. (Basel)"},{"issue":"11","key":"10.1016\/j.biopha.2025.118058_bib123","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/mnfr.201600048","article-title":"Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-alpha-dependent gene expression","volume":"60","author":"Zhang","year":"2016","journal-title":"Mol. Nutr. Food Res"},{"issue":"32","key":"10.1016\/j.biopha.2025.118058_bib124","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1021\/acs.jafc.7b02442","article-title":"Antimelanogenic Effect of Urolithin A and Urolithin B, the Colonic Metabolites of Ellagic Acid, in B16 Melanoma Cells","volume":"65","author":"Wang","year":"2017","journal-title":"J. Agric. Food Chem."},{"issue":"18","key":"10.1016\/j.biopha.2025.118058_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184466","article-title":"Preclinical testing techniques: paving the way for new oncology screening approaches","volume":"15","author":"van Rijt","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib126","article-title":"Innovative human three-dimensional tissue-engineered models as an alternative to animal testing","volume":"7","author":"Bedard","year":"2020","journal-title":"Bioeng. (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib127","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1021\/jf0527403","article-title":"Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities","volume":"54","author":"Larrosa","year":"2006","journal-title":"J. Agric. Food Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib128","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jf902857v","article-title":"Effects of fruit ellagitannin extracts, ellagic acid, and their colonic metabolite, urolithin A, on Wnt signaling","volume":"58","author":"Sharma","year":"2010","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.biopha.2025.118058_bib129","doi-asserted-by":"crossref","first-page":"1137783","DOI":"10.3389\/fphar.2023.1137783","article-title":"Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7","volume":"14","author":"Chandrasekaran","year":"2023","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib131","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/ptr.8215","article-title":"The interplay of exercise and polyphenols in cancer treatment: a focus on oxidative stress and antioxidant mechanisms","volume":"38","author":"Wang","year":"2024","journal-title":"Phytother. Res"},{"issue":"21","key":"10.1016\/j.biopha.2025.118058_bib132","doi-asserted-by":"crossref","first-page":"10181","DOI":"10.1021\/jf9025794","article-title":"Urolithins, intestinal microbial metabolites of Pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay","volume":"57","author":"Bialonska","year":"2009","journal-title":"J. Agric. Food Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib133","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/a-0755-7715","article-title":"The activity of urolithin A and M4 valerolactone, colonic microbiota metabolites of polyphenols, in a prostate cancer in vitro model","volume":"85","author":"Stanislawska","year":"2019","journal-title":"Planta Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib134","article-title":"The metabolite urolithin-A ameliorates oxidative stress in neuro-2a cells, becoming a potential neuroprotective agent","volume":"9","author":"Casedas","year":"2020","journal-title":"Antioxid. (Basel)"},{"issue":"36","key":"10.1016\/j.biopha.2025.118058_bib135","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/jf302600q","article-title":"Ellagic acid and polyhydroxylated urolithins are potent catalytic inhibitors of human topoisomerase II: an in vitro study","volume":"60","author":"Furlanetto","year":"2012","journal-title":"J. Agric. Food Chem."},{"issue":"16","key":"10.1016\/j.biopha.2025.118058_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202000289","article-title":"A hybrid in silico\/in vitro target fishing study to mine novel targets of urolithin A and B: a step towards a better comprehension of their estrogenicity","volume":"64","author":"Dellafiora","year":"2020","journal-title":"Mol. Nutr. Food Res"},{"issue":"15","key":"10.1016\/j.biopha.2025.118058_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.202300009","article-title":"PhysiologicallY-based Pharmacokinetic Modeling of the Postbiotic Supplement Urolithin A predicts its bioavailability is orders of magnitude lower than concentrations that induce toxicity, but also neuroprotective effects","volume":"67","author":"Aichinger","year":"2023","journal-title":"Mol. Nutr. Food Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib138","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44279","article-title":"Effect of Urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial","volume":"5","author":"Liu","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib139","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00223-023-01145-5","article-title":"Mitophagy activation by urolithin A to target muscle aging","volume":"114","author":"Faitg","year":"2024","journal-title":"Calcif. Tissue Int"},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib140","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4103\/jrpp.jrpp_11_24","article-title":"Efficacy of an oral solution containing five herbal extracts in the treatment of urolithiasis: a randomized, single-blind, placebo-controlled clinical trial","volume":"12","author":"Samandarian","year":"2023","journal-title":"J. Res Pharm. Pr."},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib141","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1039\/C5FO00669D","article-title":"Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers","volume":"6","author":"Li","year":"2015","journal-title":"Food Funct."},{"issue":"11","key":"10.1016\/j.biopha.2025.118058_bib142","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1039\/C4FO00542B","article-title":"Walnut polyphenol metabolites, urolithins A and B, inhibit the expression of the prostate-specific antigen and the androgen receptor in prostate cancer cells","volume":"5","author":"Sanchez-Gonzalez","year":"2014","journal-title":"Food Funct."},{"key":"10.1016\/j.biopha.2025.118058_bib143","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.phymed.2018.03.054","article-title":"The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide","volume":"46","author":"Stanislawska","year":"2018","journal-title":"Phytomedicine"},{"issue":"22","key":"10.1016\/j.biopha.2025.118058_bib144","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/jnci\/93.22.1687","article-title":"Androgen receptor signaling in androgen-refractory prostate cancer","volume":"93","author":"Grossmann","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7150\/ijbs.8264","article-title":"Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases","volume":"10","author":"Gelman","year":"2014","journal-title":"Int J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib146","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3892\/mmr.2014.2171","article-title":"XIAP underlies apoptosis resistance of renal cell carcinoma cells","volume":"17","author":"Yang","year":"2018","journal-title":"Mol. Med Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118058_bib147","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156811","article-title":"Gut microbiota conversion of dietary ellagic acid into bioactive phytoceutical urolithin A inhibits heme peroxidases","volume":"11","author":"Saha","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118058_bib148","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.fct.2013.06.025","article-title":"In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells","volume":"59","author":"Qiu","year":"2013","journal-title":"Food Chem. Toxicol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib149","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.tiv.2015.04.008","article-title":"In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells","volume":"29","author":"Wang","year":"2015","journal-title":"Toxicol. Vitr."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pros.24076","article-title":"A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance","volume":"81","author":"Jarrard","year":"2021","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib151","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/acs.jafc.6b04538","article-title":"Neuroprotective effects of bioavailable polyphenol-derived metabolites against oxidative stress-induced cytotoxicity in human neuroblastoma SH-SY5Y cells","volume":"65","author":"Gonzalez-Sarrias","year":"2017","journal-title":"J. Agric. Food Chem."},{"issue":"10","key":"10.1016\/j.biopha.2025.118058_bib152","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1158\/1940-6207.CAPR-12-0423","article-title":"A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy","volume":"6","author":"Freedland","year":"2013","journal-title":"Cancer Prev. Res (Philos. )"},{"issue":"21","key":"10.1016\/j.biopha.2025.118058_bib153","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/pmic.201200084","article-title":"Proteomic exploration of the impacts of pomegranate fruit juice on the global gene expression of prostate cancer cell","volume":"12","author":"Lee","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.biopha.2025.118058_bib154","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.fct.2016.10.005","article-title":"Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21","volume":"97","author":"Zhou","year":"2016","journal-title":"Food Chem. Toxicol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118058_bib155","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1158\/1078-0432.CCR-08-3053","article-title":"MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor","volume":"15","author":"Li","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib156","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1053\/j.gastro.2006.02.057","article-title":"Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines","volume":"130","author":"Meng","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib157","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2007.05.022","article-title":"MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer","volume":"133","author":"Meng","year":"2007","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.biopha.2025.118058_bib158","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/sj.onc.1210856","article-title":"MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer","volume":"27","author":"Asangani","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib159","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/pros.22900","article-title":"Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis","volume":"75","author":"Naiki-Ito","year":"2015","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib160","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00394-019-02016-2","article-title":"Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner","volume":"59","author":"Mohammed Saleem","year":"2020","journal-title":"Eur. J. Nutr."},{"issue":"3","key":"10.1016\/j.biopha.2025.118058_bib161","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00394-015-0924-z","article-title":"Urolithin A causes p21 up-regulation in prostate cancer cells","volume":"55","author":"Sanchez-Gonzalez","year":"2016","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.biopha.2025.118058_bib162","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/247504","article-title":"Pomegranate juice metabolites, ellagic acid and urolithin A, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis","volume":"2013","author":"Vicinanza","year":"2013","journal-title":"Evid. Based Complement Altern. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib163","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-017-0721-9","article-title":"Tumor-related interleukins: old validated targets for new anti-cancer drug development","volume":"16","author":"Setrerrahmane","year":"2017","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib164","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2174\/1568009617666170109110816","article-title":"The linkage between inflammation and immune tolerance: interfering with inflammation in cancer","volume":"17","author":"Rogovskii","year":"2017","journal-title":"Curr. Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020192","article-title":"Immunomodulatory role of urolithin A on metabolic diseases","volume":"9","author":"Toney","year":"2021","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib166","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00394-020-02386-y","article-title":"Comparative studies of urolithins and their phase II metabolites on macrophage and neutrophil functions","volume":"60","author":"Bobowska","year":"2021","journal-title":"Eur. J. Nutr."},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/metabo8040086","article-title":"Urolithin A is a dietary microbiota-derived human aryl hydrocarbon receptor antagonist","volume":"8","author":"Muku","year":"2018","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib168","doi-asserted-by":"crossref","first-page":"24","DOI":"10.15698\/cst2020.01.210","article-title":"Kynurenine: an oncometabolite in colon cancer","volume":"4","author":"Venkateswaran","year":"2020","journal-title":"Cell Stress"},{"issue":"13","key":"10.1016\/j.biopha.2025.118058_bib169","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib170","first-page":"159","article-title":"Recent development and future prospects of molecular targeted therapy in prostate cancer","volume":"15","author":"Zhang","year":"2022","journal-title":"Curr. Mol. Pharm."},{"issue":"21","key":"10.1016\/j.biopha.2025.118058_bib171","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med"},{"issue":"15","key":"10.1016\/j.biopha.2025.118058_bib172","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"32","key":"10.1016\/j.biopha.2025.118058_bib173","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 Gene Alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2025.118058_bib174","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118058_bib175","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.2147\/CMAR.S227583","article-title":"Darolutamide: an evidenced-based review of its efficacy and safety in the treatment of prostate cancer","volume":"12","author":"Crawford","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"23","key":"10.1016\/j.biopha.2025.118058_bib176","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib177","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11523-022-00944-4","article-title":"Relugolix: a review in advanced prostate cancer","volume":"18","author":"Shirley","year":"2023","journal-title":"Target Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib178","first-page":"43","article-title":"and S. Stephen, Management of advanced prostate cancer with relugolix: illustrative case scenarios from an advanced practice provider perspective","volume":"15","author":"Thorley","year":"2024","journal-title":"J. Adv. Pr. Oncol."},{"issue":"9747","key":"10.1016\/j.biopha.2025.118058_bib179","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.biopha.2025.118058_bib180","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib181","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib182","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2025.118058_bib183","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118058_bib184","doi-asserted-by":"crossref","DOI":"10.2196\/54086","article-title":"Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: phase II Single-Arm Trial","volume":"13","author":"Jain","year":"2024","journal-title":"JMIR Res Protoc."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib185","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clgc.2024.01.013","article-title":"Carboplatin in metastatic castrate resistant prostate cancer: a retrospective study of heavily pretreated patients (COMPACT)","volume":"22","author":"Pemberton","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib186","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1470-2045(17)30168-7","article-title":"Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial","volume":"18","author":"Chi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118058_bib187","first-page":"65","article-title":"Nilutamide: an antiandrogen for the treatment of prostate cancer","volume":"31","author":"Dole","year":"1997","journal-title":"Ann. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib188","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0022-5347(05)67032-2","article-title":"Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup","volume":"164","author":"Iversen","year":"2000","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib189","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40495-023-00333-z","article-title":"Wnt signaling and therapeutic resistance in castration-resistant prostate cancer","volume":"9","author":"Kishore","year":"2023","journal-title":"Curr. Pharm. Rep."},{"key":"10.1016\/j.biopha.2025.118058_bib190","article-title":"Niclosamide in prostate cancer: an inhibitor of AR-V7, a mitochondrial uncoupler, or more?","volume":"35","author":"Sakellakis","year":"2023","journal-title":"Cancer Treat. Res Commun."},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib191","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib192","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib193","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1016\/j.apsb.2023.03.013","article-title":"Emerging roles of aurora-A kinase in cancer therapy resistance","volume":"13","author":"Zheng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28083385","article-title":"Aurora B inhibitors as cancer therapeutics","volume":"28","author":"Kovacs","year":"2023","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.biopha.2025.118058_bib195","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-5347(01)64924-3","article-title":"Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal","volume":"157","author":"Small","year":"1997","journal-title":"J. Urol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib196","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N. Engl. J. Med"},{"issue":"3-4","key":"10.1016\/j.biopha.2025.118058_bib197","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07357909009012056","article-title":"Mechanisms of action and clinical uses of estramustine","volume":"8","author":"Benson","year":"1990","journal-title":"Cancer Invest"},{"issue":"11","key":"10.1016\/j.biopha.2025.118058_bib198","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"issue":"8","key":"10.1016\/j.biopha.2025.118058_bib199","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081959","article-title":"Androgen flare after LHRH initiation is the side effect that makes most of the beneficial effect when it coincides with radiation therapy for prostate cancer","volume":"14","author":"Nasser","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib200","first-page":"220","article-title":"Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial","volume":"46","author":"Vogelzang","year":"1995","journal-title":"Zoladex Prostate Study Group. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118058_bib201","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1464-410X.1991.tb15195.x","article-title":"Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma","volume":"67","author":"Kaisary","year":"1991","journal-title":"Br. J. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118058_bib202","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12325-016-0466-7","article-title":"Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer","volume":"34","author":"Breul","year":"2017","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2025.118058_bib203","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s12325-016-0351-4","article-title":"An update on triptorelin: current thinking on androgen deprivation therapy for prostate cancer","volume":"33","author":"Merseburger","year":"2016","journal-title":"Adv. Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T19:50:16Z","timestamp":1759002616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":203,"alternative-id":["S0753332225002525"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118058","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118058"}}